Personalized mRNA melanoma vaccine shows promise for 2025 approval

A groundbreaking personalized mRNA vaccine designed to fight melanoma is on track for approval in the US, Europe, and the UK next year. The vaccine represents a fundamental shift in how we treat one of skin cancer’s deadliest forms, offering new hope to thousands of patients annually.

The trial results, announced more recently after Moderna’s August announcement, involved over 1,100 adults who had undergone surgery to remove high-risk melanomas. These were tumors with a significant likelihood of recurring or spreading. In the UK alone, roughly 25 percent of the 19,400 annual melanoma diagnoses fall into this high-risk category.

How the Vaccine Works

Unlike traditional one-size-fits-all medications, this vaccine is bespoke. Researchers sequence the genetic mutations in each patient’s cancer cells and compare them to healthy DNA from the same individual. This pinpoints mutations unique to that person’s tumor. The vaccine then encodes mRNA instructions for proteins matching up to 34 of those mutations, creating what experts call “a fingerprint of proteins specifically associated with the cancer.”

The approach builds on proven science from COVID-19 mRNA vaccines, but applies it directly to cancer treatment. When administered alongside pembrolizumab, a standard immunotherapy that prevents immune T-cells from becoming exhausted, the combination proved remarkably effective.

Two years into treatment, 82 percent of patients receiving the vaccine plus pembrolizumab remained cancer-free, compared to 70 percent on pembrolizumab alone. While side effects were comparable between groups, experts note this 12-point improvement is substantial for late-stage melanoma patients.

Real-World Impact and Cost Concerns

Experts are cautiously optimistic about regulatory approval timelines. “I think approval could be quick, and next year sounds reasonable,” says Alan Melcher at the Institute of Cancer Research in London. Rebecca Lee from the University of Manchester agrees approval is “highly likely” in the US and Europe next year, potentially benefiting thousands of UK patients.

But enthusiasm comes with a significant caveat: cost. Because each vaccine must be individually manufactured, it’s expected to be prohibitively expensive. A Reuters report from January suggested a price tag around $200,000 per treatment. This raises serious questions about whether Britain’s National Health Service will deem it cost-effective for widespread use, despite the clinical benefits.

“If it was a cheap drug, I’d definitely say it will get approved for NHS use, but it’s going to be expensive,” Lee explains.

What’s Next for Personalized Cancer Treatment

Researchers emphasize that more work remains. Further studies are needed to identify which patients will benefit most from the vaccine. Some people may have mutations that fail to trigger an immune response as predicted, or existing immunotherapy might already be so effective that adding a vaccine provides no additional benefit.

Identifying blood or tumor markers that predict patient responses could eventually allow doctors to select the right candidates more precisely. Simultaneously, medicine researchers are exploring whether personalized vaccines could address other cancer types, including lung, bladder, and kidney cancers that typically respond to immunotherapy.

The broader implications are profound. As cancer treatment increasingly moves away from one-size-fits-all approaches toward molecular profiling and targeted interventions, vaccines that harness individual tumor genetics represent the frontier of precision science.

The long-term survival data remains to be seen. Current results measure cancer recurrence and death combined, but the follow-up period hasn’t yet revealed whether this translates to genuine improvements in overall survival. Those critical findings should emerge within a few years.

What’s clear now is that the era of personalized cancer vaccines is arriving, assuming healthcare systems can navigate the financial and logistical challenges of manufacturing individualized treatments at scale.

Source: New Scientist